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A B S T R A C T
Background: Huánuco is a central eastern region of Peru whose geography includes high forest and low
jungle, as well as a mountain range that constitutes the inter-Andean valleys. It is considered a region
endemic for dengue due to the many favorable conditions that facilitate transmission of the virus.
Methods: A total of 268 serum samples from patients in Huánuco, Peru with an acute febrile illness were
assessed for the presence of dengue virus (DENV) via RT-PCR and NS1, IgM, and IgG ELISA during
December 2015 and March 2016.
Results: DENV was detected in 25% of samples via RT-PCR, 19% of samples by NS1 antigen ELISA, and 10.5%
of samples by IgM ELISA. DENV IgG was detected in 15.7% of samples by ELISA. The most frequent
symptoms associated with fever across all groups were headache, myalgia, and arthralgia, with no
signiﬁcant difference between the four test methods
Conclusions: In this study, DENV was identiﬁed in up to 25% of the samples using the standard laboratory
method. In addition, a correlation was established between the frequency of positive results and the
serological tests that determine NS1, IgM, and IgG. There is an increasing need for point-of-care tests to
strengthen epidemiological surveillance in Peru.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Dengue is a major public health concern with up to 3.9 billion
people in 128 countries at risk of the disease (Moreira et al., 2018;* Corresponding author at: Universidad Peruana de Ciencias Aplicadas, Av. San
Marcos cuadra 2, Chorrillos, Lima, Peru.
E-mail address: juana.delvalle@upc.pe (J. del Valle-Mendoza).
1 Carlos Palomares-Reyes and Wilmer Silva-Caso contributed equally to this
article.
https://doi.org/10.1016/j.ijid.2019.01.022
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Brady et al., 2012). It is the most rapidly spreading mosquito-borne
viral disease, with a 30-fold increase in global incidence over the
past ﬁve decades (World Health Organization, 2012). The World
Health Organization (WHO) estimates that the incidence of dengue
virus (DENV) infection is about 50 million to 100 million cases per
year (WHO, 2009), with more than 100 endemic countries and a
documented further spread to previously unaffected areas (Mood
and Mardani, 2017). In the Americas alone, the last report in 2015
mentioned 2.35 million DENV infections, of which 10 200 cases
were considered as severe dengue, with 1181 deaths (World Healthiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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underestimate of the real prevalence and burden of the disease,
given the underreporting, misclassiﬁcation, and limitations of the
health systems in some countries, particularly those within Africa
and the Americas (Suaya et al., 2009; Beatty et al., 2011). Peru is
included in the group of the 20 most highly endemic countries in
the world according to ﬁgures reported to the WHO until 2010
(World Health Organization, 2012). Huánuco is a region of Peru
considered endemic for DENV, and in 2016, the region of Huánuco
reported its highest incidence in the last decade (Centro Nacional
de Epidemiología, 2018).
The transmission of DENV is maintained through a human–
mosquito–human cycle that involves mosquitoes of the genus
Aedes, principally Aedes aegypti (Mood and Mardani, 2017;
Omokoko et al., 2014). There are four antigenically related but
distinct dengue viruses, described as serotypes DENV-1, 2, 3, and 4.
All four serotypes are capable of causing an infection that induces a
primary immune response, leading to long-term protection against
only the homologous serotype. However, if a secondary infection
with a different serotype occurs, the immune response can lead to
a more severe dengue fever presentation in some cases (Megawati
et al., 2017). The incubation period ranges from 3 to 14 days and
symptoms usually develop between 4 and 7 days after the vector
bite (Fukusumi et al., 2016). In 2009, the WHO introduced a revised
classiﬁcation scheme comprising three categories: dengue without
warning signs, dengue with warning signs, and severe dengue that
includes the clinical features of dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) (World Health Organization,
2009). It is estimated that 50 million to 100 million cases per year
of infection with DENV manifest with symptoms (Bhatt et al.,
2013). Of these clinically apparent DENV infections, most affect
adult patients because DENV infections are commonly asymptom-
atic or minimally symptomatic in children (Endy, 2002; Cobra
et al., 1995).
One of the main requirements for control of the disease is
timely and accurate laboratory diagnosis. The diagnosis can be
made via nucleic ampliﬁcation, serology, or antigen detection.
Reverse transcriptase PCR (RT-PCR) is a highly sensitive and
speciﬁc diagnostic tool that can be used in both clinical and public
health surveillance settings, due to its ability to provide a positive
result during the ﬁrst 5 days of the disease (Darwish et al., 2015;
Santiago et al., 2013). On the other hand, immunoglobulins IgM
and IgG and non-structural protein 1 (NS1) are commonly used in
serological detection. The most widely used approach is IgM ELISA
because IgM can be detected as early as 4 days after the onset of the
disease and in more than 80% of patients with dengue (Rai et al.,
2017; Simmons et al., 2012; Teoh et al., 2015). The NS1 antigen can
be detected in DENV-infected patients from day 1 up to day 18 after
symptom onset and high levels of circulating NS1 correlate with
disease severity (Buonora et al., 2017). NS1 can be detected either
directly by lateral ﬂow rapid test, also known as immunochro-
matographic assay (Ambrose et al., 2017), or by ELISA until 9 days
later, when RNA detection becomes negative (Sawant et al., 2017).
This study was performed to evaluate the usefulness and
applicability of diagnostic tools, i.e., RT-PCR and NS1, IgM, and IgG
ELISA, in patients with clinically suspected dengue in an endemic
region of central eastern Peru.
Materials and methods
Study location
The study was conducted in the region of Huánuco during
December 2015 and March 2016 within primary health care
centers managed by the Leoncio Prado Health Network of the
Ministry of Health in Peru and within the Contingence Hospital ofTingo María. Patients who fulﬁlled the inclusion criteria were
recruited. The primary health care facilities included in the study
were the Health Center Luyando, José Crespo Castillo, Mariano
Damaso Beraun, Daniel Alomia Robles, Hermilio Valdizan, Monzon,
and Tingo María Hospital.
Study subjects
The inclusion criteria were patients diagnosed with an acute
febrile syndrome, deﬁned as fever higher than 38 C for 7 days,
without an identiﬁable source of infection and associated with one
or more of the following signs and symptoms: headache, myalgia,
arthralgia, retro-ocular pain, lower back pain, cutaneous rash,
hyporexia, odynophagia, nausea, emesis, abdominal pain, asthenia,
syncope, hypothermia, and jaundice.
Signs suggestive of coagulopathies (epistaxis, bleeding gums,
petechiae, ecchymosis, bloody sputum, hematemesis, and melena)
and signs indicating central nervous system involvement (neck
rigidity and altered mental state) were also considered.
Patients of both sexes were included, without any age
restriction. The exclusion criteria were patients with an incomplete
record of their medical data and patients with an identiﬁable
source of infection, such as an acute upper respiratory tract
infection, pneumonia, sinusitis, or urinary tract infection, among
others. Physicians used a standardized questionnaire to collect
demographic and clinical symptom information.
Ethics statement
This study was approved by the Research Ethics Board of the
Hospital Regional Docente de Cajamarca, Peru. Informed consent
was obtained from all of the study participants according to the
research protocol. For underage participants, informed consent
was obtained from their parents or their respective guardians
before enrollment.
Samples
A total of 268 samples were collected using Vacuette Serum
Separator Clot Activator tubes (Vacuette, Greiner Bio-One,
Kremsmünster, Austria). All samples were stored at 80 C after
collection and transported to Lima (Peru) under standardized
frozen conditions for further molecular assays.
RNA extraction
RNA extraction from 200 ml of the serum sample was
performed using the High Pure RNA Isolation Kit (Roche Applied
Science, Mannheim, Germany), following the manufacturer’s
instructions. Viral RNA obtained after extraction was eluted in
100 ml of nuclease-free water and then processed or stored at 20
C until use.
Real-time RT-PCR assay for the detection of DENV and serotypes with
TaqMan probe
A one-step RT-PCR was performed using TaqMan with BHQ
quencher probe at 125 nM and 250 nM of primers in a ﬁnal volume
of 20 ml. Five microliters of the extracted RNA was combined with
15 ml of the Master Mix and the reverse transcription step was
performed as follows: 95 C for 15 min, 60 cycles of 15 s at 95 C and
45 s at 60 C. All procedures were performed in a LightCycler 2.0
instrument and data were analyzed with LightCycler software 4.1
(Roche Diagnostics, Mannheim, Germany). The primers and the
probe used have been described previously by Leparc-Goffart
(Leparc-Goffart et al., 2009) (Supplementary Material, Table S1).
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The presence of DENV NS1 antigen was detected by Euroimmun
ELISA (Euroimmun AG, Lübeck, Germany). DENV IgM and IgG
antibodies were also detected using Euroimmun ELISA (Euro-
immun AG, Lübeck, Germany). Each serum sample was run in
duplicate, in accordance with the manufacturer’s instructions.
Statistical analysis
The patient data were entered into a Microsoft Access database
designed for this study. They were then tabulated in a Microsoft
Excel ﬁle with the counting function, and the respective tables
were prepared to show the data in a consolidated and summarized
manner. Graphics were generated using OriginPro v.10 software.
The prevalence rates of positives and negatives were analyzed
using the Chi-square test. The diagnostic accuracy was analyzed to
estimate conﬁdence intervals (95% CI) for sensitivity, speciﬁcity,
and two-level likelihood ratios. Age characteristics were analyzed
using analysis of variance (ANOVA), adjusted to models of a normal
distribution and represented in a box-chart. The matrices of
clinical signs and symptoms were compared using the paired t-
test. The correlation scatter matrices were established with the
Pearson coefﬁcient (r) and the area established at the 95% CI.
Differences were considered statistically signiﬁcant if the p-value
was <0.05.
Results
In this study, a total of 268 samples from patients diagnosed
with an acute febrile illness (AFI) were analyzed to determine the
frequency of DENV infection.
Figure 1 shows that the frequency of DENV as determined by
RT-PCR method was 25.75%; this was signiﬁcantly higher (p < 0.05)
than the frequencies obtained by ELISA for NS1 (19.03%) and IgM
(10.45%). The frequency of positive IgG (15.67%), indicating a past
or secondary infection by DENV, is also shown independently.
Thus, the RT-PCR method was used as the reference method in the
subsequent analyses (Supplementary Material, Table S2).
The diagnostic accuracy of the methods used was evaluated by
determining the sensitivity and speciﬁcity indexes (Table 1).
Comparison of the RT-PCR test with the immunological tests based
on the detection of the NS1 antigen and IgM showed sensitivities of
42% and 13%, respectively. These values indicate the conditional
probability of a positive diagnosis by means of the respective ELISA
test with respect to the positive cases by RT-PCR for DENV. On theFigure 1. Frequency of dengue virus in the affected population with an acute febrile
illness (AFI) during 2016 (Huánuco, Peru).other hand, the conditional probability of obtaining a negative
result by immunological tests with respect to negative cases by RT-
PCR corresponds to the speciﬁcity of the immunological tests;
these showed values close to 90%. However, regarding the
immunological tests, the diagnosis of DENV by NS1 was found
to be superior because the probability of ﬁnding a positive case was
about four times higher than in the group of subjects affected by an
AFI without DENV infection.
Finally, from a detailed analysis of the diagnostic tests for DENV
(Table 1), it can be concluded that the diagnostic accuracy ordered
from highest to lowest is as follows: RT-PCR > NS1 ELISA > IgM
ELISA.
In this study, no signiﬁcant biases were found for the diagnosis
of DENV according to the sex of the patient (Figure 2). Also, the age
of the patients was not a determinant associated with DENV
infection (Figure 3). Figure 3 shows that the age distribution of
those affected by an AFI corresponded to a normal distribution
(ANOVA, p < 0.05), and a similar distribution was obtained for cases
with a positive diagnosis for dengue regardless of the diagnostic
method used (Supplementary Material, Table S3).
The population affected by an AFI corresponded to an adult
population with a mean  standard deviation age of 26  16 years
(95% CI 24–28 years; median 22 years). The population with a
positive diagnosis of DENV by RT-PCR was characterized by an
average age of 28  16 years (95% CI 24–32 years; median 26 years).
Similarly, in the populations found positive by immunological
methods via the detection of NS1 and IgM, the majority
corresponded to an adult group with a mean age of 30  17 years
(95% CI 25–35 years; median 28 years) and 28  15 years (95% CI
22–34 years; median 27 years), respectively. Other statistical
parameters of the populations studied are shown in Figure 3.
An important aspect in the determination of the etiology of the
disease is the clinical diagnosis based on signs and symptoms.
When the frequencies of signs and symptoms were compared
between the total population of AFI patients and the patients
diagnosed with DENV, no signiﬁcant differences were observed
(Figure 4a). This is clearly shown through correlation analysis
between the total AFI population and the AFI population with a
diagnosis of DENV infection (Figure 4b), in which highly positive
correlations were observed. However, more detailed analysis with
consideration of the odds ratio allowed some differences to be
established for the patients diagnosed with DENV (Figure 4c).
Thus, the odds ratio of RT-PCR was found to be signiﬁcantly
different compared to the diagnosis by NS1 (paired t-test,
p = 0.036). Although the odds ratio varied in a similar way and
the correlation was acceptable (Figure 4d), a higher incidence of
headache, myalgia, and odynophagia in the population diagnosed
by RT-PCR could be responsible for these differences, by having a
greater strength of positive association with the presence of
dengue conﬁrmed by the test. RT-PCR and NS1 showed clear
differences compared to the IgM-positive cases (paired t-test,
p = 0.012 and p = 0.004, respectively) (Supplementary Material,
Table S4). These differences correspond to negative correlations
(Figure 4d), which can be explained by the higher incidence of
signs and symptoms that are infrequent in the population with AFI
(e.g., petechiae, bleeding gums, bloody sputum, chest pains, etc.).
These minority signs and symptoms appeared in patients
diagnosed with IgG and although their incidence was lower than
in patients diagnosed with IgM (paired t-test, p = 0.003), they are
directly related to a secondary infection by DENV. The same clinical
trend was observed in these groups of patients according to the
correlation coefﬁcient obtained for both (r = 0.6178). Overall, this
indicates that a matrix based on signs and symptoms is too
complex for a presumptive diagnosis of dengue infection.
Table 1
Diagnostic accuracy; RT-PCR is the gold standard or diagnostic of reference.
Index Reference test
RT-PCRa NS1a IgMa
Diagnostic test NS1 Sensitivity 0.420 (0.311–0.538)
Speciﬁcity 0.889 (0.838–0.926)
PLR 3.80 (2.35–6.16)
NLR 0.65 (0.53–0.80)
DOR 5.83 (3.04–11.19)
IgM Sensitivity 0.130 (0.070–0.229) 0.412 (0.287–0.548)
Speciﬁcity 0.904 (0.856–0.938) 0.968 (0.935–0.984)
PLR 1.37 (0.65–2.88) 12.76 (5.74–28.39)
NLR 0.96 (0.87–1.06) 0.61 (0.48–0.77)
DOR 1.42 (0.61–3.31) 21.00 (8.23–53.60)
IgG Sensitivity 0.362 (0.259–0.480) 0.765 (0.632–0.860) 0.679 (0.493–0.821)
Speciﬁcity 0.914 (0.868–0.946) 0.986 (0.960–0.995) 0.904 (0.860–0.935)
PLR 4.24 (2.44–7.37) 54.55 (17.55–169.52) 7.08 (4.45–11.27)
NLR 0.70 (0.58–0.84) 0.24 (0.14–0.39) 0.36 (0.21–0.61)
DOR 6.08 (3.02–12.23) 228.58 (61.65–847.56) 19.92 (8.08–49.09)
PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio.
a Values are presented with the 95% conﬁdence interval in parenthesis.
Figure 2. Distribution of the frequency of female and male patients.
Figure 3. Box-chart of the age distribution.
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serotype DENV-2 and 17 could not be typed, which constitutes a
limitation of this study.Discussion
Peru is one of the 100 countries affected with dengue fever.
During 2016, Peru registered a total of 31868 cases of DENV
infection, of which 3855 were dengue with warning signs and 124
were severe dengue cases, and there were 41 deaths secondary to
DENV (Centro Nacional de Epidemiologia, 2018). Huánuco is a
region located in central Peru that has experienced a two-fold
increase in its population during the last 7 years, with 172 924
inhabitants in the last report from 2014 (INEI). Furthermore,
Huánuco is one of the Peruvian localities with the highest Aedes
index, which ranges from 1.4% to 11.69% (Centro Nacional de
Epidemiologia, 2018).
In the present study, a total of 268 serum samples from patients
with an AFI were assessed for the presence of DENV using
molecular diagnostic methods during December 2015 and March
2016. A total of 69 (25.7%) positive DENV cases were identiﬁed, of
which 46 (66.7%) occurred during January and February. This
ﬁnding correlates with the peak incidence in Huánuco, described
as occurring during the sixth epidemiological week by the
Peruvian Ministry of Health (Centro Nacional de Epidemiologia,
2018). Furthermore, it can be explained by the increase of 2 C in
maximum local temperature (SENAMHI, 2016) and the increase in
precipitation rate (accumulated rainfall of 300 mm/week) reported
in Huánuco during January and February of 2016 (Centro Nacional
de Estimación, 2016), which may have created better climate
conditions for the transmission of DENV by the Aedes mosquitoes.
In relation to the diagnosis, several studies reported in the
literature have assessed the usefulness of the available diagnostic
methods to identify DENV. IgM ELISA is one of the most widely
used techniques in many public health care centers (Hunsperger
et al., 2014).
A case–control study comparing seven commercial antigen
antibody ELISAs for the detection of DENV described sensitivity
values ranging from 86% to 91% and speciﬁcity values ranging from
82% to 93% for Panbio IgM ELISA, and values of 81–88% and 93–99%,
respectively, for Standard Diagnostics ELISA IgM, with a 95%
conﬁdence interval (Suleman et al., 2016). In an analysis by
Hunsperger et al. (2014), the sensitivity of Venture E ELISA IgM was
97% for primary DENV infections compared to 96% for secondary
DENV infections, and the speciﬁcity was 84% against the DENV-
negative panel (Hunsperger et al., 2014). However, other studies
have reported lower diagnostic accuracy values, such as a study
from Malaysia by Kassim et al., in which a sensitivity of 40.9% was
described for Panbio IgM ELISA (Kassim et al., 2011), and a study
Figure 4. Signs and symptoms associated with a presumptive diagnosis of dengue virus infection.
Frequency distribution (a) and odds ratio (c) of signs and symptoms. Correlation analysis between frequencies (b) and odds ratio (d) of the signs and symptoms.
C. Palomares-Reyes et al. / International Journal of Infectious Diseases 81 (2019) 31–37 35published in 2016 by Ashwini et al. that reported a 47.9% positive
detection rate for IgM ELISA (Anand et al., 2016). In the present
study, a sensitivity of 13.0% and speciﬁcity of 90.4% was found for
IgM ELISA when compared with RT-PCR as the reference test. The
lower sensitivity and speciﬁcity values may be explained by the
differences in performance characteristics related to patient
infection status. Primary DENV infections typically have a stronger
and more speciﬁc IgM response; consequently, IgM-positive rates
in secondary infections are not as high as in primary infections, and
in some secondary DENV infections, IgM may not be detected at all,
as evidenced in the medical literature (Brady et al., 2012; Chanama
et al., 2004).
NS1 is a multifunctional glycoprotein that plays important roles
in immune evasion, pathogenesis, and the early stage of viral
replication (Scaturro et al., 2015). It can be detected in the sera of
infected patients during the acute phase of illness, which typically
refers to the ﬁrst week of illness, although some reports indicatethat it can be detectable up until 9–10 days after the ﬁrst
appearance of signs and symptoms (Suleman et al., 2016; Guzman
et al., 2010; Krishnananthasivam et al., 2015). The sensitivity of NS1
detection depends on the technique used and whether the sample
corresponds to a primary or secondary infection. In primary
infection, the sensitivity can exceed 90%, while in secondary
infection, the sensitivity is lower and ranges from 60% to 80%
(Guzman et al., 2010; Hunsperger et al., 2016). Gaikwad et al.
reported a concordance between ELISA NS1 and RT-PCR of 100%
from day 3 to day 8 (Sawant et al., 2017). Ahmed et al. reported the
sensitivity, speciﬁcity, positive predictive value, and negative
predictive value of NS1 ELISA to be 73.53%, 100%, 100%, and 70%,
respectively (Shrivastava et al., 2011), while Hunsperger et al.
reported 60–75% sensitivity and 71–80% speciﬁcity for NS1 ELISA
(Hunsperger et al., 2014). The present study found a sensitivity of
42.0%, speciﬁcity of 88.9%, positive likelihood ratio (PLR) of 3.8, and
negative likelihood ratio (NLR) of 0.65 for NS1 ELISA; this was the
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compared with RT-PCR. Although the reported sensitivity of NS1
ELISA was almost four-fold that of IgM ELISA, the value remains
lower than those reported in the cited literature. This could be the
result of immune complex formation during secondary infection,
which impairs NS1 detection by ELISA (Buonora et al., 2017). Some
studies have also reported lower NS1 ELISA sensitivity in DENV-4
infections compared with infections caused by other serotypes, in
both primary and secondary infections (da Costa et al., 2014).
Patients with symptomatic DENV infections go through three
clinical phases: a febrile phase, a critical phase, and a recovery
phase. The febrile phase is characterized by sudden high-grade
fever, usually 38.5 C, accompanied by unspeciﬁc symptoms such
as headache, myalgia, and transient macular rash or by alarming
symptoms such as persistent vomiting and abdominal pain (World
Health Organization, 2009). In the present study, the most
common symptoms among the total study population were
headache (97.1%), myalgia (94.2%), and arthralgia (91.3%), and
the same frequency distribution was found in RT-PCR-positive
patients, with 92.9% presenting headache, 86.19% presenting
myalgia, and 85.07% presenting arthralgia. Although the literature
mentions that rash occurs in approximately half of the cases, only
18 (26.09%) DENV-infected patients in the present study developed
a macular rash. The lower prevalence found could be explained by
the fact that rash is more common during primary infection than
secondary infection (Cobra et al., 1995) and 60.87% of the studied
samples corresponded to secondary DENV infections, based on the
positive results of IgG ELISA in relation to the total positives by RT-
PCR. The present study showed that ﬁve (7.24%) cases corre-
sponded to dengue fever with alarming signs. All ﬁve (100%) were
primary infections, and four patients (5.97%) presented abdominal
pain and one patient (1.45%) developed thrombocytopenia. No
cases of severe dengue and no deaths occurred. As mentioned
before, when the frequencies of signs and symptoms were
compared between the total AFI patients and those who were
positive for DENV, no signiﬁcant differences were observed (Figure
4a). Also, the correlation scatter matrices made for clinical
symptoms and diagnostic methods showed a positive correlation
(r > 0.98) when the symptom frequencies were compared (Figure
4b) and a negative correlation between IgM ELISA and RT-PCR
(r = 0.23) and between IgM ELISA and NS1 ELISA (r = 0.14) for
symptom odds ratios (Figure 4d). Overall, it was indicated that the
matrix based on signs and symptoms was too complex to establish
any statistically signiﬁcant relationship between clinical manifes-
tations of DENV infection and the diagnostic methods used for the
detection of DENV in the present study.
Conclusions
In this study, DENV was identiﬁed in up to 25.74% of patients
with an AFI via the detection of DENV RNA by RT-PCR. In addition, a
correlation was established between the frequency of positive
results and the serological tests that determine NS1, IgM, and IgG. It
was found that there was a greater correlation between RT-PCR and
NS1 ELISA for the diagnosis of acute DENV infection. There is a
growing need for conﬁrmatory diagnostic laboratory tests for
clinically deﬁned dengue cases to strengthen epidemiological
surveillance in endemic areas.
Finally, it is concluded that the diagnostic accuracy of the tests
investigated can be ordered from highest to lowest as follows: RT-
PCR > NS1 ELISA > IgM ELISA.
Circulating serotypes of DENV should be monitored closely for
the prevention of disease with alarming signs and serious illness.Limitations
The main limitation of this study is that the study design
focused only on the detection of DENV, thus other potentially
circulating pathogens such as chikungunya virus, Zika virus,
Mayaro virus, and Oropouche virus, which have been described in
Peru and can cause AFI, cannot be excluded. These arboviruses,
although less common than DENV, might have been present in the
DENV-negative samples or could have been present as co-
infections. Additionally, the causality between the different
serotypes and clinical presentation could not be established.
Finally, it was only possible to classify 52 of the 69 positive
samples, leaving 17 samples that were positive for DENV but not
typed.
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